

GLAXOSMITHKLINE PLC
Form 6-K
December 24, 2008

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending December 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

This
announcement replaces
the original announcements
released on
6 May 2008
at 16.30 ;
4 August 20
08
at 18.11
;
and
7 November 20
08
at 18.02
.

The Administrators of the GlaxoSmithKline Performance Share Plan (the "Plan") notified the Company on 8 December 2008 of a correction to the market price of Ordinary shares used to calculate the number of shares reinvested under the dividend reinvestment element of the Plan for participants who both received Ordinary shares and who were detailed in the affected original announcements, in respect of dividends paid to shareholders on 10 July 2008

.
The market price of Ordinary shares should have read £11.21 (rather than £11.20), and the participants' increased interests in Ordinary shares have been corrected.

Given the cumulative nature of dividend reinvestment, the correction in respect of the payment made on 10 July 2008 also had a minor impact on the calculation of the dividends reinvested for the affected Plan participants in respect of the payments made on 9 October 2008 and 8 January 2009

.
Details in respect of JP Garnier, C Viehbacher and SM Werner are excluded from these replacements as JP Garnier and C Viehbacher are no longer directors of the Company, and SM Werner is no longer deemed a Person Discharging Managerial Responsibility.

Save as disclosed above, all other details remain unchanged.

**Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons**

The administrators of the GlaxoSmithKline Performance Share Plan
(the "Administrators")
notified the Company and
the under
-mentioned
person
s
on
6 May
2008

of
an
increase in
their notional
interests

in
Ordinary
shares
at a price of £
11.21
per share
and
Ordinary
Share
ADRs at
a price of \$
44.11
per ADR

following the notional re-investment of the dividend
paid to shareholders on
10 July 2008

	Ordinary shares	ADRs
Mr A P Witty	4,600.76	
Mr J S Heslop	3,738.77	
Dr M M Slaoui	332.61	1
		657.54

Mrs C E Bruck Slaoui	26.51	37.72
Mr J M Clarke	2,787.62	
Mr M Dunoyer	1,049.88	
Mr E J Gray	870.19	
Mr R G Greig		917.26
Mr D Learmouth	573.25	
Mr W C Louv		666.68
Mr D J Phelan		1,412.58
Dr D Pulman		917.26

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transaction

s notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell
Company Secretary

6 May 2008

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the Company and the under-mentioned persons on 4 August 2008 of an increase in their notional interests in Ordinary shares at a price of £11.67 per share and Ordinary Share ADRs at a price of \$46.53 per ADR

following the notional re-investment of the dividend paid to shareholders on 9 October 2008.

	Ordinary shares	ADRs
Mr A P Witty	5,161.32	
Mr J S Heslop	3,633.05	

Dr M M Slaoui	323.20	1,591.48
Mrs C E Bruck Slaoui	25.76	36.21
Mr S M Bicknell	272.17	
Mr J M Clarke	2,708.79	
Mr M Dunoyer	1,020.19	
Mr E J Gray	845.58	
Mr S A Hussain	500.36	
Mr D Learmouth	557.04	
Mr W C Louv		640.11
Mr D		1,356.28
J Phelan		
Dr D Pulman		880.70
Mr D S Redfern	415.11	
Mr J R Stéphenne	935.76	
Ms C Thomas	312.39	

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to
transaction

s
notified in accordance with
Disclosure and Transparency R
ule
s 3.1.4R(1)(a).

S M Bicknell
Company Secretary

4 August 2008

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the
Company and
the under-mentioned

person

s

on 7 November
2008 of an increase in their notional interest

s

in Ordinary shares at a price of £

11.66

per share and Ordinary Share ADRs at a price of \$37.32 per ADR

following the notional re-investment of the dividend
to be
paid to shareholders on
8 January 2009

	Ordinary shares	ADRs
Mr A P Witty	5,625.	
	08	
Mr J S Heslop	3,959.49	
Dr M M Slaoui	352.24	1,835.07
Mrs C E Bruck Slaoui	28.07	41.75
Mr S M Bicknell	296.63	
Mr J M Clarke	2,952.18	
Mr M Dunoyer	1,111.86	
Mr E J Gray	921.56	
Mr S A Hussain	545.32	
Mr D Learmouth	607.09	
Mr W C Louv		738.09
Mr D J Phelan		1,563.87
Dr D Pulman		1015.50
Mr D S Redfern	452.41	
Mr J R Stéphenne	1,019.84	
Ms C Thomas	340.46	

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with

Disclosure and Transparency Requirements

ule
s
3.1.4R(1)(a)
.

Victoria A Whyte
Deputy
Company Secretary

7 November 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: December 24, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc